---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-318056"
form_type: "8-K"
ticker: "APVO"
cik: "0001671584"
company_name: "Aptevo Therapeutics Inc."
filed_at: "2026-07-27T20:05:18+00:00"
generated_at: "2026-07-27T20:06:06.909613+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Aptevo files patent for Nectin-4 x PD-L1 dual-targeting backbone; new solid tumor strategy

## Summary
- Patent filing covers proprietary Nectin-4 x PD-L1 dual-targeting backbone for solid tumors.
- Backbone may be adapted into radiopharmaceuticals, T-cell engagers, and immune-based therapies.
- Strategy aims to enhance tumor targeting and anti-tumor immunity by targeting both Nectin-4 and PD-L1.
- Filing strengthens IP portfolio and supports platform-driven approach for multiple assets and partnerships.

## SEC filing metadata
- accession: 0001193125-26-318056
- form_type: 8-K
- ticker: APVO
- cik: 0001671584
- company_name: Aptevo Therapeutics Inc.
- filed_at: 2026-07-27T20:05:18+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1671584/000119312526318056/0001193125-26-318056-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1671584/000119312526318056/apvo-20260727.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-318056
- JSON: https://secwatch.observer/filing/0001193125-26-318056.json
- Plain text: https://secwatch.observer/filing/0001193125-26-318056.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.